Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Substituted aminoquinolone and aminothiazole scaffolds: BayerRecent Research Landscape

Tumor-induced immune suppression limits the efficacy of immunotherapy, which is mitigated by the precise structural modification of heterocyclic inhibitors to selectively modulate DGK isoforms. These specific chemical scaffolds provide the necessary binding affinity to reactivate T-cell signaling while minimizing off-target toxicity.

What technical problems is Bayer addressing in Substituted aminoquinolone and aminothiazole scaffolds?

Tumor immune evasion

(43)evidences

Inadequate stimulation of the immune system limits the efficacy of treatments for oncology or chronic infections. Enhancing this response provides a therapeutic advantage in overcoming disease-mediated immunosuppression.

Insufficient hemostatic pathway control

(15)evidences

Endogenous natriuretic peptides suffer from rapid proteolytic degradation and renal clearance. Grafting these peptides onto antibody scaffolds prevents premature metabolic breakdown and extends therapeutic circulation time.